Grabar Law Office is investigating claims on behalf of shareholders of GRAIL, Inc. (NASDAQ: GRAL). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.

WHY? As alleged in a recently filed securities fraud class action complaint, GRAIL, Inc. (NASDAQ: GRAL), through certain of its officers, violated federal securities laws by making false and/or misleading statements regarding the likelihood that the Company's landmark NHS-Galleri cancer screening trial would achieve its primary endpoint of demonstrating a statistically significant reduction in late-stage (Stage III and IV) cancers. According to the complaint, defendants repeatedly highlighted positive interim metrics, including favorable positive predictive value and other performance indicators, while allegedly creating the impression that the trial was on track to deliver its key clinical objective. The complaint further alleges that defendants failed to disclose material information suggesting that the study's design and follow-up period may have been insufficient to demonstrate the primary endpoint within the anticipated timeframe.

The truth allegedly emerged on February 19, 2026, when GRAIL announced that the NHS-Galleri trial failed to achieve its primary endpoint of a statistically significant reduction in Stage III-IV cancers. Although the Company emphasized certain positive findings, including reductions in Stage IV cancer diagnoses and increased detection of earlier-stage cancers, the complaint alleges that investors learned for the first time that the primary endpoint had not been met and that additional follow-up may be necessary to adequately assess the trial's effectiveness. Following the announcement, GRAIL's stock price fell more than 50% in a single trading day, causing substantial losses to investors.

WHAT CAN YOU DO NOW? If you purchased GRAIL, Inc. (NASDAQ: GRAL) shares prior to May 13, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  You are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  Alternatively, if you purchased GRAIL shares between May 13, 2025 and February 19, 2026, you can participate in the class action.